Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2017 1
2018 2
2020 4
2021 2
2022 4
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia.
Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, Jaén-Olasolo P. Saceda-Corralo D, et al. Int J Trichology. 2017 Jul-Sep;9(3):143-145. doi: 10.4103/ijt.ijt_73_16. Int J Trichology. 2017. PMID: 28932074 Free PMC article. No abstract available.
Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice.
Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Saceda-Corralo D, et al. J Drugs Dermatol. 2022 Jul 1;21(7):742-747. doi: 10.36849/JDD.6610. J Drugs Dermatol. 2022. PMID: 35816059
OBJECTIVE: The main objective was to describe the safety profile of mesotherapy with dutasteride in real clinical practice in a large cohort of patients with androgenetic alopecia. ...No serious or sexual adverse events were detected. CONCLUSION: Mesotherapy
OBJECTIVE: The main objective was to describe the safety profile of mesotherapy with dutasteride in real clinical practice in …
Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review.
Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, de León-Gutiérrez H, Ocampo-Garza SS, Gómez-Flores M, Grimalt R. Herz-Ruelas ME, et al. Skin Appendage Disord. 2020 Nov;6(6):338-345. doi: 10.1159/000510697. Epub 2020 Oct 9. Skin Appendage Disord. 2020. PMID: 33313048 Free PMC article. Review.
Mesotherapy could be a feasible alternative to avoid systemic exposure and side effects [J Pan-Arab League Dermatologist. 2009 Feb;20(1):137-45]. ...Although both interventions favor over placebo, there are not enough data to reliably compare outcomes obtained between both
Mesotherapy could be a feasible alternative to avoid systemic exposure and side effects [J Pan-Arab League Dermatologist. 2009 Feb;20
Two Cases of Paradoxical Nonscarring Alopecia after Mesotherapy with Dutasteride.
Reguero Del Cura L, De Quintana Sancho A, Rubio Lombraña M, López Sundh AE, González López MA. Reguero Del Cura L, et al. Skin Appendage Disord. 2022 Jan;8(1):46-48. doi: 10.1159/000518043. Epub 2021 Aug 18. Skin Appendage Disord. 2022. PMID: 35118130 Free PMC article.
Alopecia after mesotherapy with dutasteride is an extremely rare complication. Dutasteride is a second-generation 5a-reductase enzyme inhibitor that decreases serum dihydrotestosterone levels by 90%. ...We present 2 cases of patchy alopecia after mesothera
Alopecia after mesotherapy with dutasteride is an extremely rare complication. Dutasteride is a second-generation 5a-re …
Frontal edema due to mesotherapy for androgenetic alopecia: A case series.
Melo DF, Saceda-Corralo D, Tosti A, Weffort F, Carla Jorge M, de Barros CC, de Melo Carvalho R, Starace M. Melo DF, et al. Dermatol Ther. 2022 Feb;35(2):e15247. doi: 10.1111/dth.15247. Epub 2021 Dec 13. Dermatol Ther. 2022. PMID: 34877759
Although minimally invasive, mesotherapy may be related to mild side effects like burning, erythema and headaches, as a few reports indicate. ...In all our cases of edema, lidocaine was the anesthetic used. Minoxidil and dutasteride might also play a role as causati …
Although minimally invasive, mesotherapy may be related to mild side effects like burning, erythema and headaches, as a few reports i …
Novel drug delivery approaches for the management of hair loss.
Alsalhi W, Alalola A, Randolph M, Gwillim E, Tosti A. Alsalhi W, et al. Expert Opin Drug Deliv. 2020 Mar;17(3):287-295. doi: 10.1080/17425247.2020.1723543. Epub 2020 Feb 6. Expert Opin Drug Deliv. 2020. PMID: 32003262 Review.
What's New in Therapy for Male Androgenetic Alopecia?
Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R. Saceda-Corralo D, et al. Am J Clin Dermatol. 2023 Jan;24(1):15-24. doi: 10.1007/s40257-022-00730-y. Epub 2022 Sep 28. Am J Clin Dermatol. 2023. PMID: 36169916
While there are different treatments to stop hair loss and improve hair density, the 5-alpha reductase inhibitors have demonstrated to be effective in improving androgenetic alopecia in men and can maintain a positive response for many years. Oral finasteride 1 mg is a US FDA-app …
While there are different treatments to stop hair loss and improve hair density, the 5-alpha reductase inhibitors have demonstrated to be ef …
Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation.
Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, Ibrahim M. Moftah N, et al. J Eur Acad Dermatol Venereol. 2013 Jun;27(6):686-93. doi: 10.1111/j.1468-3083.2012.04535.x. Epub 2012 Apr 6. J Eur Acad Dermatol Venereol. 2013. PMID: 22486925
OBJECTIVE: Evaluation of the efficacy and safety of mesotherapy using dutasteride-containing preparation in treatment of FPHL. ...Ultrastructural evaluation was done for three patients. RESULTS: After mesotherapy with dutasteride-containing preparation …
OBJECTIVE: Evaluation of the efficacy and safety of mesotherapy using dutasteride-containing preparation in treatment of FPHL. …
Angioedema-like contact dermatitis caused by mesotherapy with dutasteride.
Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, Martínez-Domenech Á, Alonso-Carpio M, Talamantes CS, Zaragoza-Ninet MG, Zaragoza-Ninet V. Magdaleno-Tapial J, et al. Contact Dermatitis. 2020 Sep;83(3):246-247. doi: 10.1111/cod.13585. Epub 2020 Jul 1. Contact Dermatitis. 2020. PMID: 32356373 No abstract available.
13 results